Duchenne Group: 'Venture Philanthropy' Could Spur Medical Innovation

Patient groups interested in spurring the development of new treatments should consider implementing a "venture philanthropy" model that could allow them to be more involved in innovative research, Cure Duchenne President Debra Miller told FDA Week . For example, Cure Duchenne recently established a $7 million collaboration with biotech company Prosensa to advance the development of four drugs, including one expected to be submitted to FDA later this year. Miller also encouraged groups to get involved in research early, increasing...